A Randomized Trial of Hydroxychloroquine as Post-exposure Prophylaxis for

Abstract

Research revealed that in vitro activity ofchloroquine and the derivative molecule of hydroxychloroquine is against the infection caused by the SARS-CoV and SARS-CoV-2. The US FDA approved the use of both hydroxychloroquinesulfate and chloroquine phosphate for the critical patients of COVID-19. The clinical trials supported that the hydroxychloroquine did not substantially reduce the system severity in non-hospitalized persons. Moreover, it also produces severe side effects like drowsiness, hypokalaemia, nausea, convulsions, shock, and even death.